Clinical epidemiology and management challenges of genital Mycoplasma and Ureaplasma infections: a retrospective observational study at a Japanese urban clinic
Abstract
BACKGROUND: Genital Mycoplasmas and Ureaplasmas pose diagnostic and therapeutic challenges due to their varying pathogenicity and increasing antimicrobial resistance. This study aimed to characterise the positivity, clinical associations, and treatment outcomes of Mycoplasmoides genitalium, Metamycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum in an urban clinic in Tokyo, Japan.
METHODS: This retrospective study was conducted at a single clinic in Tokyo, Japan. Electronic medical records of patients who underwent polymerase chain reaction testing for the four target pathogens between January 2023 and April 2024 were included in the study. To minimise confounding, a sub-analysis was performed on a chlamydia/gonorrhoea-negative subset. The statistical association between specific organisms and symptoms was assessed, and the treatment success rate (negative test-of-cure after ≥3 weeks) was evaluated.
RESULTS: Of 524 patients tested, 213 (40.7%) tested positive for at least one pathogen. M. genitalium was the most prevalent (81/213, 38.0%), and showed a robust association with dysuria (P < 0.01) and purulent genital discharge (P = 0.03) in the chlamydia/gonorrhoea-negative subset. In contrast, M. hominis and Ureaplasma spp. were predominantly associated with colonisation or non-specific symptoms. The clinical success rate for M. genitalium (minocycline followed by sitafloxacin) was suboptimal at 68.8%. Notably, U. parvum showed an alarmingly low success rate…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 524 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.